| 2018 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice | JOURNAL OF THORACIC ONCOLOGY |
| 2018 | Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival | LUNG CANCER |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2023 | Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments
| CANCERS |
| 2023 | Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
| Cancer Treatment and Research Communications |
| 2009 | Clinical value of ezrin expression in primary osteosarcoma
| CANCER RESEARCH AND TREATMENT |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | ANNALS OF ONCOLOGY |
| 2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2017 | Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
| ONCOTARGET |
| 2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
| 2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| ONCOTARGET |
| 2022 | Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma
| CLINICAL AND TRANSLATIONAL MEDICINE |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2009 | Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials.
| CANCER RESEARCH AND TREATMENT |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2018 | Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
| 2018 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. | CANCER RESEARCH |
| 2018 | ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma | ONCOGENE |
| 2020 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
| BMC CANCER |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | LUNG CANCER |
| 2021 | Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy
| CANCERS |
| 2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| SCIENTIFIC REPORTS |
| 2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |
| 2020 | Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
| IMMUNE NETWORK |
| 2019 | Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2019 | Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide study | Gastroenterology & Hepatology |
| 2022 | Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity
| FRONTIERS IN ONCOLOGY |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
| 2023 | Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer | NATURE CANCER |
| 2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
| 2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2022 | Lazertinib: on the Way to Its Throne
| YONSEI MEDICAL JOURNAL |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
| PLOS ONE |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2019 | Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
| PLOS ONE |
| 2021 | Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents
| KIDNEY RESEARCH AND CLINICAL PRACTICE |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2021 | Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2021 | Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
| SCIENTIFIC REPORTS |
| 2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| SCIENTIFIC REPORTS |
| 2016 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
| SCIENTIFIC REPORTS |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
| 2023 | Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2023 | Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies
| CANCERS |
| 2017 | Povidone-iodine for the management of oral mucositis during cancer therapy
| Oncology Reviews |
| 2023 | Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC | CLINICAL CANCER RESEARCH |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
| 2022 | Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor
| YONSEI MEDICAL JOURNAL |
